Quantum BioPharma Insiders Lift Voting Control to 68% Via C$80.86 MVS Placement; Reverse-Split Authority Approved
QNTM is trading near its 52-week low of $1.91 (4.7% above the low).
Summary
Quantum BioPharma closed a C$80.86 placement of 26 Class A Multiple Voting Shares to two insider vehicles, lifting their combined voting control to about 68%. Shareholders also approved authority for a reverse split of up to 10-for-1 and a name change.
Key Events · Corporate Governance and Compliance · QNTM
-
Insider MVS Placement Closes
26 Class A Multiple Voting Shares were issued at C$3.11 each for aggregate gross proceeds of C$80.86, priced off the US$2.21 Nasdaq trading price of the Class B shares on November 9, 2026.
-
Insider Voting Control Jumps to 68%
Xorax Family Trust (CEO Zeeshan Saeed) and Fortius Research and Trading Corp. (director Anthony Durkacz) each acquired 13 shares, moving combined voting power from approximately 57.01% to approximately 68.22%.
-
Reverse Split Authority Approved
A special resolution lets the board consolidate shares at up to 10 pre-consolidation shares for 1 post-consolidation share, at its discretion; 97.0% of votes cast were in favor.
-
Name Change Authority Approved
Shareholders authorized a company name change at the board's discretion, with 97.6% support.
Analysis · QNTM · Life Sciences
Two insider vehicles — Xorax Family Trust (CEO Zeeshan Saeed) and Fortius Research and Trading Corp. (director Anthony Durkacz) — each bought 13 Class A Multiple Voting Shares at C$3.11, lifting their combined voting power from roughly 57% to roughly 68%. The cash raised is trivial (C$80.86 total), so this is a control transaction, not a capital raise: the dual-class structure lets insiders hold a supermajority of votes while owning a small slice of the equity. Shareholders also authorized a consolidation of up to 10-for-1 and a name change, both at the board's discretion — with the stock at $2.00 and near its 52-week low of $1.91, a reverse split is a plausible next step to defend the Nasdaq listing. Minority holders should note the MVS Issuance Resolution passed with only 65.8% support, with 34.2% voting against.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $1.91 to $12.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.